Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 9/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30442255 | 0.86 | MAOB (0.62) | KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3151885 | 0.86 | MAOB (0.62) | KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2868546 | 0.86 | KMT2A (0.61) | KMT2ANR4A2MRGPRX4AKR1C3NR4A1 | |
| SCHEMBL6356224 | 0.85 | KMT2A (0.47) | KMT2ANR4A2MRGPRX4RAB9ANPC1 | |
| SCHEMBL3069825 | 0.85 | MRGPRX4 (0.56) | KMT2AMRGPRX4RAB9ANPC1TP53 | |
| SCHEMBL28124115 | 0.85 | PARP1 (0.67) | KMT2A | |
| SCHEMBL1665041 | 0.85 | KMT2A (0.73) | KMT2ANR4A2MRGPRX4AKR1C3NR4A1 | |
| SCHEMBL30517635 | 0.85 | KMT2A (0.73) | KMT2ANR4A2MRGPRX4AKR1C3NR4A1 | |
| SCHEMBL9368628 | 0.84 | ESR1 (0.52) | KMT2ANR4A2PKMSMN1; SMN2 | |
| SCHEMBL7516815 | 0.83 | KMT2A (0.48) | KMT2AMRGPRX4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-105593339-A | Polymerizable liquid crystal compound, and liquid crystal composition and optical film comprising same | LG CHEMICAL LTD | 2016-05-18 | — | — | CN | disclosed |
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | disclosed |
| US-5380854-A | Anticoagulants for surgery | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0600084-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5254576-A | Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993003012-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | KMT2A 4568/4885NR4A2 1531/4885MRGPRX4 255/4885 |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | KMT2A 4568/4885NR4A2 1531/4885MRGPRX4 255/4885 |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | KMT2A 3426/4885NR4A2 1624/4885MRGPRX4 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.